Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric IBD Studies Should Assess Disease Activity, Panel Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.

Advertisement

Related Content

FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach
Would Sponsors Do Earlier Pediatric IBD Studies With Nod From Agency Or Advisory Committee?
Gastroenterology Endpoints For IBD Drugs Once Again In FDA Spotlight
Gastroenterology Endpoints To Get Four-Day Series Of FDA Workshops
Pediatric Study Plans Would Be Required At End Of Phase II Under Bipartisan House Bill
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004964

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel